title: Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
abstract: BACKGROUND
  The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood.
  
  
  OBJECTIVE
  To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status.
  
  
  METHODS
  COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing-remitting MS treated with subcutaneous interferon beta-1a.
  
  
  RESULTS
  In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, and 163 received interferon beta-1a, 22 µg subcutaneously three times weekly). Mean MS Quality of Life-54 (MSQoL-54) composite scores did not change over time. There were no significant differences between groups in MSQoL-54 composite scores when patients were grouped by treatment dose and baseline cognitive status. Mean (standard deviation) Hamilton Depression Rating Scale score decreased from 6.8 (4.9) at baseline to 5.8 (5.9) at year 3. Mean total Fatigue Impact Scale scores were low (<30) at all time points.
  
  
  CONCLUSIONS
  Quality of life, depression and fatigue remained largely stable over 3 years; no effects of treatment dose or baseline cognitive status were found.
authors.affiliation: Multiple Sclerosis Centre Sicilia Region, First Neurology Clinic, University Hospital, Catania, Italy. patti@unict.it
authors.forename: F
authors.initials: F
authors.lastname: Patti
authors.forename: M P
authors.initials: MP
authors.lastname: Amato
authors.forename: M
authors.initials: M
authors.lastname: Trojano
authors.forename: S
authors.initials: S
authors.lastname: Bastianello
authors.forename: M R
authors.initials: MR
authors.lastname: Tola
authors.forename: O
authors.initials: O
authors.lastname: Picconi
authors.forename: S
authors.initials: S
authors.lastname: Cilia
authors.forename: S
authors.initials: S
authors.lastname: Cottone
authors.forename: D
authors.initials: D
authors.lastname: Centonze
authors.forename: C
authors.initials: C
authors.lastname: Gasperini
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005221:Fatigue / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a